Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Equity Ratio (2020 - 2026)

Maxcyte has reported Equity Ratio over the past 6 years, most recently at 0.85 for Q4 2025.

  • Quarterly Equity Ratio fell 1.68% to 0.85 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.85 through Dec 2025, down 1.68% year-over-year, with the annual reading at 0.85 for FY2025, 1.68% down from the prior year.
  • Equity Ratio was 0.85 for Q4 2025 at Maxcyte, roughly flat from 0.84 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.95 in Q3 2021 and troughed at 0.84 in Q3 2025.
  • The 5-year median for Equity Ratio is 0.88 (2024), against an average of 0.88.
  • Year-over-year, Equity Ratio skyrocketed 44.2% in 2021 and then dropped 6.6% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.93 in 2021, then fell by 4.25% to 0.89 in 2022, then decreased by 2.32% to 0.87 in 2023, then fell by 0.48% to 0.86 in 2024, then fell by 1.68% to 0.85 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Equity Ratio are 0.85 (Q4 2025), 0.84 (Q3 2025), and 0.87 (Q2 2025).